Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency.
作者信息
Tafuri Giovanni, Trotta Francesco, Leufkens Hubert G M, Pani Luca
出版信息
Br J Clin Pharmacol. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424.x.
Abstract
摘要
相似文献
1
Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency.欧洲撤回和拒绝申请理由的披露：监管透明度方面的一项进展。
Br J Clin Pharmacol. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424.x.
2
European ombudsman questions European Medicines Agency over AbbVie redactions.欧洲申诉专员就艾伯维公司的删节内容质问欧洲药品管理局。
BMJ. 2014 Nov 18;349:g6904. doi: 10.1136/bmj.g6904.
3
French law to make conflict of interest disclosure mandatory.
Nat Med. 2011 Sep 7;17(9):1026. doi: 10.1038/nm0911-1026a.
4
Europe's opportunity to open up drug regulation.
BMJ. 2010 Mar 30;340:c1578. doi: 10.1136/bmj.c1578.
5
European Medicines Agency--more transparency needed.欧洲药品管理局——需要更高的透明度。
Lancet. 2010 May 22;375(9728):1753. doi: 10.1016/S0140-6736(10)60785-4.
6
A future for regulatory science in the European Union: the European Medicines Agency's strategy.欧盟监管科学的未来：欧洲药品管理局的战略。
Nat Rev Drug Discov. 2020 May;19(5):293-294. doi: 10.1038/d41573-020-00032-0.
7
[Consequences of the 12th AMG amendment on the conduct of non-commercial clinical trials].[《第12次《药品法》修订案对非商业性临床试验开展的影响》]
Urologe A. 2005 Dec;44(12):1444-8. doi: 10.1007/s00120-005-0944-z.
8
European drug agency's attempts to improve transparency stalled by legal action from two US drug companies.欧洲药品管理局提高透明度的努力因两家美国制药公司的法律诉讼而受阻。
BMJ. 2013 Jun 3;346:f3588. doi: 10.1136/bmj.f3588.
9
Roche medical director could face GMC if the company withheld relevant data on oseltamivir.
BMJ. 2012 Dec 11;345:e8408. doi: 10.1136/bmj.e8408.
10
European Union scrambles to revise drug approval laws.
Lancet. 2003 Jun 14;361(9374):2056. doi: 10.1016/S0140-6736(03)13684-7.
引用本文的文献
1
A Retrospective Analysis of Applications for Registration of Generic Medicines Processed by the Medicines Control Authority of Zimbabwe.津巴布韦药品管制管理局处理的仿制药注册申请的回顾性分析。
Ther Innov Regul Sci. 2023 Mar;57(2):287-294. doi: 10.1007/s43441-022-00469-y. Epub 2022 Oct 21.
2
Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.心肌毒性和心力衰竭：人诱导多能干细胞衍生心肌细胞和抗癌药物的教训。
Cells. 2020 Apr 17;9(4):1001. doi: 10.3390/cells9041001.
3
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.2014-2016 年新药上市申请中 EMA 和 FDA 决策的比较：一致性、不一致性及原因。
Clin Pharmacol Ther. 2020 Jan;107(1):195-202. doi: 10.1002/cpt.1565. Epub 2019 Aug 14.
4
Recognizing that Evidence is Made, not Born.认识到证据是被制造出来的，而不是天生的。
Clin Pharmacol Ther. 2019 Apr;105(4):844-856. doi: 10.1002/cpt.1317. Epub 2019 Jan 4.
5
Comparison of a teratogenic transcriptome-based predictive test based on human embryonic versus inducible pluripotent stem cells.基于人类胚胎干细胞与诱导多能干细胞的致畸转录组预测测试的比较。
Stem Cell Res Ther. 2016 Dec 30;7(1):190. doi: 10.1186/s13287-016-0449-2.
6
Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.人诱导多能干细胞衍生心肌细胞中蒽环类药物诱导的心脏毒性的基因组生物标志物鉴定：一种用于安全性评估的体外重复暴露毒性方法。
Arch Toxicol. 2016 Nov;90(11):2763-2777. doi: 10.1007/s00204-015-1623-5. Epub 2015 Nov 4.
7
Regulating prescription drugs for patient safety: does Bill C-17 go far enough?为保障患者安全规范处方药：C-17法案力度够吗？
CMAJ. 2014 May 13;186(8):E287-92. doi: 10.1503/cmaj.131850. Epub 2014 Mar 10.
本文引用的文献
1
European Medicines Agency--more transparency needed.欧洲药品管理局——需要更高的透明度。
Lancet. 2010 May 22;375(9728):1753. doi: 10.1016/S0140-6736(10)60785-4.
2
Transparency at the Food and Drug Administration.美国食品药品监督管理局的透明度。
N Engl J Med. 2010 Jun 24;362(25):2341-3. doi: 10.1056/NEJMp1005202. Epub 2010 May 19.
3
New drug approval success rate in Europe in 2009.2009年欧洲新药获批成功率。
Nat Rev Drug Discov. 2010 May;9(5):355-6. doi: 10.1038/nrd3169.
4
Europe's opportunity to open up drug regulation.
BMJ. 2010 Mar 30;340:c1578. doi: 10.1136/bmj.c1578.
5
The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.提交至欧洲药品评估局的药物申请审评：常见异议及结果
Eur J Clin Pharmacol. 2002 Dec;58(9):573-80. doi: 10.1007/s00228-002-0532-8. Epub 2002 Nov 13.
Zotero 插件